Drug Use and Addiction Research Programs (93.279)
Drug Use and Addiction Research Programs (Assistance Listing 93.279) is run by the National Institutes of Health, part of the Department of Health and Human Services. It awarded $7.3 billion in 5,071 grants from fiscal 2021 to 2025, about $1.4 million per award on average. 109 funding opportunities are open or forecast now.
The typical award was $728,927. Half of the 5,071 awards fell between $320,000 and $1.8 million, and they ranged from $0 to $74.1 million.
- Awarded, FY 2021 to 2025$7.3 billion
- Grant awards5,071
- Typical award$728,927
- Awarded in FY 2025$1.5 billion
- Size rank67 of 1,823
- Type of assistanceProject grants, training
Key findings
- Annual funding rose from $1.4 billion in fiscal 2021 to $1.5 billion in fiscal 2025.
- It is the 67th largest of 1,823 federal grant programs by five-year awards.
- The 20 largest recipients received 38% of the money.
- Awards went to recipients in 50 states and territories.
What the program funds
To support basic, clinical, translational, and implementation research in the field of substance use. To develop new knowledge and approaches for the prevention, diagnosis, and treatment of drug use, misuse, and addiction, drug overdose, and related health outcome, including HIV/AIDS. To support research training and research scientist development. To support dissemination of research findings. Small Business Innovation Research (SBIR) legislation is intended to expand and improve the SBIR programs to emphasize and increase private sector commercialization of technology developed through Federal SBIR research and development; increase small business participation in Federal research and development; and foster and encourage participation of socially and economically disadvantaged small business concerns and women-owned small business concerns in the SBIR program. The Small Business Technology Transfer (STTR) legistlation is intended to stimulate and foster scientific and technological innovation through cooperative research and development carried out between small business concerns and research institutions; foster technology transfer between small business concerns and research institutions; increase private sector commercialization of innovations derived from Federal research and development; and foster and encourage participation of socially and economically disadvantaged small business concerns and women-owned small business concerns in technological innovation.
Open and forecast opportunities
- NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional)
- Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional)
- Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)
- Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)
- Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
- Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed)
- Emerging Global Leader Award (K43 Independent Clinical Trial Required)
- NIH Research Software Engineer (RSE) Award (R50 Clinical Trials Not Allowed)
- Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)
- Intervention Research to Improve Native American Health (R34 Clinical Trial Optional)
- Intervention Research to Improve Native American Health (R01 Clinical Trial Optional)
- HEAL Initiative: Integrative Management of Chronic Pain and OUD for Whole Recovery (IMPOWR): Research Centers (RM1 Clinical Trial Required)
- HEAL Initiative: Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR) - Building Engagement, Assistance, Capacity, Outreach, and Networks (BEACON) Center (U2C Clinical Trial Not Allowed)
- Biomedical Research Environment and Sponsored Programs Administration Development (BRE-SPAD) Program (UC2- Clinical Trial Not Allowed)
- BRAIN Initiative: Preclinical Proof of Concept for Novel Recording and Modulation Technologies in the Human CNS (R18 - Clinical Trial Not Allowed)
- BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (R01 Clinical Trial Not Allowed)
- Neural Ensembles & Used Substances (NExUS) Collaboratory: Building a Multimodal Inventory of Cell Ensembles Encoding the Effects of Addictive Substances (U01 Clinical Trial Not Allowed)
- NIDA Animal Genomics Program (U01 Clinical Trial Not Allowed)
- BRAIN Initiative: Exploratory Research Opportunities Using Invasive Neural Recording and Stimulating Technologies in the Human Brain (R61 Clinical Trial Not Allowed)
- NLM Institutional Grants for Research Training in Biomedical Informatics, Data Science, and AI (T15 Independent Clinical Trial Not Allowed)
- High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
- Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)
- High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)
- NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
- NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
Rules from the program listing
Who can apply
Eligible organizations determined at the NOFO level
What the money can and cannot pay for
(1) Research project grants provide support for clearly defined projects or a small group of related research activities, and when appropriate, support of research conferences; (2) program project and center grants support large-scale, broad-based programs of research, usually interdisciplinary, consisting of several projects with a common focus; (3) small grants support newer, less experienced investigators; investigators at institutions without a well-developed research tradition and resources; the testing of new methods or techniques; small-scale exploratory and pilot studies, or exploration of an unusual research opportunity; (4) research training grants including fellowships and institutional training grants, career development grants and loan repayment contracts; (5) SBIR Phase I grants (of approximately 6-months' duration) are to establish the technical merit and feasibility of proposed research or research and development efforts to determine the quality of performance of the small business grantees. Phase II grants are for the continuation of the research initiated in Phase I and that are likely to result in commercially viable products or processes. STTR Phase I grants (normally of 1-year duration) are to determine the scientific, technical, and commercial merit and feasibility of the proposed cooperative effort that has potential for commercial application and the quality of performance of the small business concerns.
Matching requirements
This program has no statutory formula. Matching requirements are not applicable to this assistance listing. MOE requirements are not applicable to this assistance listing.
Award range and average, in the agency's words
Range-$5,724 to $27,502,167, Average-$621,479
Funding history and past recipients
From fiscal 2021 to 2025, Drug Use and Addiction Research Programs (93.279) awarded $7.3 billion across 5,071 grant awards, an average of $1.4 million per award.
Who usually wins
Colleges and universities received 70% of the money, nonprofits 17% and small businesses 8.6%.
| Recipient type | Awards | Amount | Share |
|---|---|---|---|
| Colleges and universities | 3,660 | $5.1 billion | 70% |
| Nonprofits | 771 | $1.3 billion | 17% |
| Small businesses | 403 | $632 million | 8.6% |
| Other | 214 | $295 million | 4.0% |
| Businesses | 10 | $26.3 million | 0.4% |
| State and local governments | 6 | $7.2 million | 0.1% |
| Tribal governments and organizations | 6 | $4.8 million | less than 0.1% |
| Individuals | 1 | $5,487 | 0% |
By state
48 states have a page for this program: those that received at least $1 million or 10 awards.
| State | Awards | Amount |
|---|---|---|
| California | 673 | $1.1 billion |
| New York | 453 | $773 million |
| Massachusetts | 386 | $613 million |
| Pennsylvania | 343 | $488 million |
| Maryland | 279 | $434 million |
| North Carolina | 282 | $375 million |
| Connecticut | 178 | $339 million |
| Texas | 196 | $289 million |
| Florida | 174 | $237 million |
| Washington | 173 | $235 million |
| Illinois | 142 | $202 million |
| Michigan | 121 | $171 million |
| Ohio | 96 | $161 million |
| Virginia | 119 | $159 million |
| Minnesota | 107 | $137 million |
| Missouri | 93 | $131 million |
| Kentucky | 68 | $123 million |
| New Jersey | 96 | $106 million |
| South Carolina | 94 | $101 million |
| Oregon | 94 | $98.4 million |
| Georgia | 72 | $94.9 million |
| Colorado | 84 | $94.6 million |
| Rhode Island | 111 | $93.3 million |
| Tennessee | 75 | $81.0 million |
| Indiana | 59 | $64.7 million |
| Alabama | 48 | $59.1 million |
| Utah | 37 | $58.2 million |
| Wisconsin | 47 | $55.2 million |
| Arkansas | 20 | $54.7 million |
| Arizona | 40 | $48.1 million |
| New Hampshire | 25 | $45.5 million |
| Nebraska | 39 | $45.3 million |
| New Mexico | 22 | $39.6 million |
| Maine | 13 | $36.7 million |
| District of Columbia | 34 | $31.6 million |
| Vermont | 13 | $25.4 million |
| Oklahoma | 16 | $18.9 million |
| Mississippi | 22 | $17.8 million |
| Iowa | 17 | $15.8 million |
| West Virginia | 15 | $14.3 million |
| Louisiana | 18 | $14.2 million |
| Delaware | 8 | $14.0 million |
| Montana | 8 | $8.1 million |
| Hawaii | 5 | $5.0 million |
| Kansas | 8 | $4.8 million |
| Nevada | 5 | $4.1 million |
| North Dakota | 1 | $1.3 million |
| South Dakota | 2 | $1.3 million |
| Wyoming | 1 | $856,953 |
| Puerto Rico | 5 | $416,813 |